Tag: Genome Editing

Genome Editing Market Update: Intellia Therapeutics Presents Data at the 2019 Annual Congress of the European Society of Gene and Cell Therapy

Intellia Therapeutics, one of the leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology is presenting one oral presentation and four poster presentations at the 27th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT) meeting taking place October 22-25, 2019, in Barcelona, Spain. The global genome

Gene Editing Technology: ZFN, TALEN and Meganucleases

Presently, there are several companies and universities, which are exploring the potential of gene editing technology beyond CRISPR for basic research, and the development of gene editing solutions. With the development of a versatile gene editing technology, including zinc-finger nucleases (ZFNs), TAL effector nucleases (TALENs), engineered endonucleases / meganucleases (EMNs) and clustered regularly interspaced short

Genome Editing Services Market Snapshot

The rising demand for genome editing services has resulted in the rise of several players with a wide range of capabilities. Currently, there are close to 80 players that claim to offer CRISPR based genome editing services. To get more insights about the market, check out the detailed report market report – Genome Editing Services.

Gene Editing Companies: Future Potential and Ethical Concerns

Gene editing companies around the word are debating the scientific and ethical possibilities of using powerful genome editing tools, such as the CRISPR gene editing therapies, to treat heritable diseases in human embryos. In 1987, the discovery of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated (Cas) genes in single celled prokaryotic systems revolutionized genetic engineering.